Allogeneic transplantation is considered to be a form of adoptive immunotherapy, which is active against haematological malignancies. In the absence of an HLA-identical sibling, patients can be allografted using an unrelated donor. 1 After myeloablative regimens, in vivo T-cell depletion by anti-thymocyte (ATG) or anti-lymphocyte globulins has been demonstrated to reduce the probability of GVHD and non-relapse mortality (NRM), without an enhanced risk of relapse. 2, 3 Reduced-intensity conditioning (RIC) or non-myeloablative regimens were introduced more than 10 years ago, 4, 5 and several regimens have been used with different characteristics in terms of immunoablation, myeloablation and toxicity. In this study, we report the outcomes of patients who received the same ATG-based RIC (FBA), followed by an unrelated or HLA-identical sibling donor.
From July 2005 to December 2009, we treated 109 patients with haematological malignancies with a RIC regimen, followed by unrelated donor stem cells (alloUD; N = 51) or by cells from a HLA-identical sibling (alloSIB; N = 58).
The conditioning regimen comprised fludarabine (150 mg/m 2 ), i.v. BU (6.4 mg/kg) and an intermediate dose of ATG (5 mg/kg), on days -2 and -1. PBSCs were used in all but four patients who received BM stem cells (alloUD group).
GVHD prophylaxis comprised cyclosporine alone (3 mg/kg/day), starting from day -3. Acute and chronic GVHD (aGVHD and cGVHD) diagnosis and treatment were established according to international guidelines. Unrelated donors were high-resolution HLA-A, -B, -C DRB1 and DQ matched (10/10 alleles) with their respective recipients in 37 patients, and one allelic mismatch was detected in 14 patients (9/10 alleles).
DLIs were performed in cases of stable mixed chimerism, relapse/progression or as prophylaxis in patients considered to have a high risk of relapse.
Chi-square and Mann-Whitney tests were used to compare categorical and continuous variables, respectively. The Kaplan-Meier method was used to analyse the probabilities of engraftment, OS and PFS, whereas competing risk analysis was used to calculate cumulative incidences of relapse, TRM aGVHD and cGVHD. Estimations were conducted together with their respective 95% confidence intervals (CI). A P-value of o0.05 was considered as significant.
The patient characteristics are shown in Table 1 . In alloSIB and alloUD, the median time to ANC of o0.5 × 10 6 /dL was 12 (8-31) and 14 days (11-81), and the median time to unsupported platelet count of 420 × 10 6 /L 19 days for both, that is, 5-32 and 12-81, respectively. Bacterial infections were diagnosed more frequently after alloUD than that after alloSIB (25% vs 10%, respectively; P = 0.07). CMV infections developed in 45% and 28% of patients (P = 0.09), respectively, but multiple CMV reactivations were significantly more frequent in the alloUD group (22% vs 7%; P = 0.05), even if this was not complicated by a higher incidence of CMV-related disease (three cases with gastroenteritidis in alloUD and one case with gastritis in alloSIB). BK virus-related haemorrhagic cystitis incidence was low (2% vs 5%). The incidence of invasive fungal infections was low and not different for the two patient cohorts (6% and 2%, respectively; Table 1 ).
For the alloUD and alloSIB cohorts, the incidence of grade 2-4 was 27% (CI 7-28) and 17% (CI 15-40; P = 0.02), respectively, but the incidence of grade 3-4 was not statistically different (9% vs 12%). The overall cGVHD incidence was 39% (CI 25-53) and 28% (CI 16-40; P = 0.08), respectively, and the incidence of extensive cGVHD was similar (23% vs 24%).
The 100 day, 1-and 2-year NRM rates were 4%, 12% and 20% for alloUD, and 2%, 12% and 14% for alloSIB, respectively. These differences were not statistically different.
After a median follow-up of 30 months, the 2-year OS was 65% vs 74%, and the 2-year PFS was 55% vs 65% for alloUD and alloSIB, respectively (Figure 1 ). These results were not statistically different. No difference in terms of the relapse rate at 1 year was observed between the two cohorts of patients (20% for both).
This retrospective comparison between patient cohorts receiving transplantation from a HLA-identical related or unrelated donor after RIC containing i.v. BU and intermediate doses of ATG (5 mg/kg) confirmed that there were no significant differences in terms of outcome.
We progressively tuned the RIC conceived by the Hadassah team. The main message was that using ATG for 2 days significantly reduced the incidence of aGVHD and cGVHD without negatively impacting the relapse rate, also in leukemic patients. 5, 6 The usefulness of ATG for the outcome after RIC regimens, particularly with HLA-identical siblings, is controversial. CIBMTR showed that 7 T-cell depletion by alemtuzumab or ATG reduced the risk of immunological complications, but the relapse risk and overall mortality were significantly higher with ATG. For most patients, the median dose of ATG was high (7 mg/kg), partially explaining the high relapse incidence and toxicity. Indeed, in a previous study, our group showed that higher doses of ATG (47.5 mg/kg) resulted in a lower survival because of more frequent deaths from infectious complications. 8 In this retrospective study, the adoption of 2 days of ATG seems to represent the optimal tuning of immunosuppression. Indeed, we did not observe significant differences in the incidence of bacterial, fungal and viral infections, except for multiple CMV reactivations, which were more frequent after alloUD.
The incidence of aGVHD was low, but more frequent in the alloUD group, which may be attributable to the presence of mismatched unrelated donors (25%). Chronic GVHD was also low and not significantly different between the two groups.
In this study, the relapse rate was low (20% in both groups) compared with the CIBMTR study 7 in the cohort of patients treated with ATG (relapse rate: 49%). These results should be considered with caution because the inclusion criteria and patient characteristics can drastically influence this figure.
Using a similar conditioning regimen and despite significant differences, similar results have been reported in literature. 9, 10 In conclusion, despite the limits of its retrospective nature, our study showed that fludarabine, i.v. BU and intermediate doses of ATG performed as well as using both matched and mismatched, unrelated or HLA-sibling donors.
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